Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Randomized Controlled Trial Comparing the Short-term Outcomes of Enhanced Recovery After Surgery and Conventional Care in Laparoscopic Distal Gastrectomy (GISSG1901)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Standard Setting in Simulation-Based Training of Surgical Procedures: A Systematic Review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Comment on Prehabilitation in Major Abdominal Surgery

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Impact of a Parastomal Bulge on Quality of Life - A Cross-sectional Study of Patients From the Danish Stoma Database

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reasons for staying in hospital after video-assisted thoracoscopic surgery lobectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. AHA STEROID trial, dexamethasone in acute high-risk abdominal surgery, the protocol for a randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Functional recovery after discharge in enhanced recovery video-assisted thoracoscopic lobectomy: a pilot prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Yulong Tian
  • Shougen Cao
  • Xiaodong Liu
  • Leping Li
  • Qingsi He
  • Lixin Jiang
  • Xinjian Wang
  • Xianqun Chu
  • Hao Wang
  • Lijian Xia
  • Yinlu Ding
  • Weizheng Mao
  • Xizeng Hui
  • Yiran Shi
  • Huanhu Zhang
  • Zhaojian Niu
  • Zequn Li
  • Haitao Jiang
  • Henrik Kehlet
  • Yanbing Zhou
Vis graf over relationer

OBJECTIVE: This study aimed to compare the effects of ERAS and conventional programs on short-term outcomes after LDG.

SUMMARY OF BACKGROUND DATA: Currently, the ERAS program is broadly applied in surgical areas. Although several benefits of LDG with the ERAS program have been covered, high-level evidence is still limited, specifically in advanced gastric cancer.

METHODS: The present study was designed as a randomized, multicenter, unblinded trial. The enrollment criteria included histologically confirmed cT2-4aN0-3M0 gastric adenocarcinoma. Postoperative complications, mortality, readmission, medical costs, recovery, and laboratory outcomes were compared between the ERAS and conventional groups.

RESULTS: Between April 2019 and May 2020, 400 consecutive patients who met the enrollment criteria were enrolled. They were randomly allocated to either the ERAS group (n = 200) or the conventional group (n = 200). After excluding patients who did not undergo surgery or gastrectomy, 370 patients were analyzed. The patient demographic characteristics were not different between the 2 groups. The conventional group had a significantly longer allowed day of discharge and postoperative hospital stay (6.96 vs 5.83 days, P < 0.001; 8.85 vs 7.27 days, P < 0.001); a longer time to first flatus, liquid intake and ambulation (3.37 vs 2.52 days, P < 0.001; 3.09 vs 1.13 days, P < 0.001; 2.85 vs 1.38 days, P < 0.001, respectively); and higher medical costs (6826 vs 6328 $, P = 0.027) than the ERAS group. Additionally, patients in the ERAS group were more likely to initiate adjuvant chemotherapy earlier (29 vs 32 days, P = 0.035). There was no significant difference in postoperative complications or in the mortality or readmission rates. Regarding laboratory outcomes, the procalcitonin and C-reactive protein levels on postoperative day 3 were significantly lower and the hemoglobin levels on postoperative day 5 were significantly higher in the ERAS group than in the conventional group.

CONCLUSION: The ERAS program provides a faster recovery, a shorter postoperative hospitalization length, and lower medical costs after LDG without increasing complication and readmission rates. Moreover, enhanced recovery in the ERAS group enables early initiation of adjuvant chemotherapy.

TidsskriftAnnals of Surgery
Udgave nummer1
Sider (fra-til)e15-e21
Antal sider7
StatusUdgivet - 1 jan. 2022

ID: 64955470